RxDoctor Payments Data

Sunil Khurana, MD

Gastroenterology · Poughkeepsie, NYNPI 1720082407

Payments from drug & device makers

$141,119in general payments, 2019–2025

Across 132 payments — averaging $1069.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$87K
  • Janssen Research & Development, LLC$31K
  • Gilead$13K
  • Pfizer$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • UCB Biosciences Inc.$520
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$1,97099%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$141,119 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$866,171
Medicare patients
565
Services billed
35,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine126$99,178
CreonLipase/Protease/Amylase41$72,607
LinzessLinaclotide44$38,577
XifaxanRifaximin17$37,730
ZenpepLipase/Protease/Amylase14$32,779
PentasaMesalamine18$29,212
TrulancePlecanatide30$21,627
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates239$13,806
Mesalamine ErMesalamine35$10,320
MotegrityPrucalopride Succinate12$8,483
Omeprazole623$7,405
Ursodiol35$6,830
Lubiprostone35$6,408
Pantoprazole Sodium591$6,257
Sucralfate66$6,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$87,232$111,18485 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$51$61,75464 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$3,034$8,48312 claims
Braintree Laboratories, Inc.Sutab$78$3,01919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →